Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Sapient Delivers New Online Multilingual Re To Support Thousands Of Families Affected By Rare Congenital Syndrome
Sapient (NASDAQ: SAPE) announced that it has designed and delivered a Web-based multilingual solution to support the efforts of CdLS World, an international federation of non-profit organizations committed to assisting those affected by Cornelia de Lange Syndrome (CdLS), a rare congenital disorder. While there is as yet no cure for CdLS, information and access to early therapeutic interventions and therapies is the key to helping children with CdLS reach their full potential. Sapient"s Ask the Doctor - which can be accessed at http://www.cdlsworld.org or through local CdLS country websites - brings a vast online re of up-to-date, relevant medical information to families and medical professionals around the world.
generic viagra online
Alarming Rise In Deadly Skin Cancer Cases, UK
There has been an alarming rise in new cases of the deadliest form of skin cancer in the UK, with binge tanning cited as a main reason, said a
News of the day
Teach Your Patients About Their Medicines To Avoid Misadventure, UK
The National Prescribing Service Ltd (NPS) is urging health professionals to teach patients how to identify the active ingredient in their medicines to avoid mix ups and adverse events.
Nutrition

Hebrew University Research Leads To Advanced Trials Of New Cancer Treatment

Research by a Hebrew University of Jerusalem professor has led to the development of a product that has been shown in clinical trials to be successful in halting the growth of various types of cancer cells. The research, conducted by Prof. Avraham Hochberg of the Silberman Institute of Life Sciences at the university, has won for him first prize among faculty members for this year"s Kaye Innovations Awards, which was presented on June 9 during the annual Hebrew University Board of Governors meeting. Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells. Research has also demonstrated that the H19 gene plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions, such as low serum and low oxygen levels, that are typical conditions of the environment in which cancerous cells develop. This survival supports the growth of the tumor and the development of metastases. The research and understanding of the origin of cancer and metastases has progressed significantly in recent years. In light of scientific breakthroughs in cancer research, and the role of the H19 gene in such processes, it is believed that an anti-cancer drug based on suppressing the expression of the H19 gene has the potential to provide benefits that are competitive with existing treatment methods. Prof. Hochberg"s research was patented by Yissum Research Development Company of the Hebrew University. In 2005 Yissum established BioCancell Inc., to which it licensed the technology. The company is now traded in the Tel Aviv stock exchange (TASE). BioCancell"s leading product, BC-819, has demonstrated efficacy in clinical trials (now in an advanced stage) in Israel and the US for the treatment of human bladder, pancreatic and ovarian cancers. Jerry Barach The Hebrew University of Jerusalem


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009